SAGE Therapeutics (SAGE) Upgraded to “Hold” at BidaskClub

BidaskClub upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from a sell rating to a hold rating in a research note published on Saturday morning.

SAGE has been the topic of a number of other research reports. Royal Bank of Canada reduced their price objective on SAGE Therapeutics from $145.00 to $137.00 and set an outperform rating on the stock in a research note on Monday, November 27th. SunTrust Banks set a $82.00 price objective on SAGE Therapeutics and gave the stock a buy rating in a research note on Thursday, October 19th. Chardan Capital raised SAGE Therapeutics from a neutral rating to a buy rating and lifted their price objective for the stock from $60.00 to $140.00 in a research note on Friday, November 10th. BMO Capital Markets reaffirmed a buy rating and issued a $80.00 price objective on shares of SAGE Therapeutics in a research note on Friday, October 27th. Finally, Leerink Swann lifted their price objective on SAGE Therapeutics from $85.00 to $123.00 and gave the stock a positive rating in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company. SAGE Therapeutics has an average rating of Buy and an average price target of $171.21.

SAGE Therapeutics (NASDAQ SAGE) traded down $5.55 during trading hours on Friday, reaching $186.78. The company’s stock had a trading volume of 341,910 shares, compared to its average volume of 526,557. SAGE Therapeutics has a 1-year low of $46.11 and a 1-year high of $195.97. The company has a market cap of $7,668.07, a P/E ratio of -27.19 and a beta of 2.98.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts forecast that SAGE Therapeutics will post -7.42 earnings per share for the current fiscal year.

In other news, insider Stephen Kanes sold 44,000 shares of SAGE Therapeutics stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $177.18, for a total value of $7,795,920.00. Following the completion of the transaction, the insider now owns 46,348 shares in the company, valued at approximately $8,211,938.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jeffrey M. Jonas sold 210,247 shares of SAGE Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total value of $33,103,390.15. Following the completion of the transaction, the chief executive officer now owns 211,473 shares of the company’s stock, valued at approximately $33,296,423.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 314,247 shares of company stock valued at $50,465,110. Company insiders own 6.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in SAGE Therapeutics by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after acquiring an additional 58,679 shares during the period. Bank of New York Mellon Corp boosted its holdings in SAGE Therapeutics by 36.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after acquiring an additional 724,494 shares during the period. State Street Corp boosted its holdings in SAGE Therapeutics by 7.7% during the 2nd quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after acquiring an additional 87,097 shares during the period. Oak Ridge Investments LLC boosted its holdings in SAGE Therapeutics by 0.9% during the 3rd quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock valued at $45,897,000 after acquiring an additional 6,835 shares during the period. Finally, Northern Trust Corp boosted its holdings in SAGE Therapeutics by 17.9% during the 2nd quarter. Northern Trust Corp now owns 411,444 shares of the biopharmaceutical company’s stock valued at $32,767,000 after acquiring an additional 62,474 shares during the period. Hedge funds and other institutional investors own 95.48% of the company’s stock.

TRADEMARK VIOLATION WARNING: “SAGE Therapeutics (SAGE) Upgraded to “Hold” at BidaskClub” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2018/02/04/sage-therapeutics-sage-upgraded-to-hold-at-bidaskclub.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit